Pharmacokinetic (PK)/pharmacodynamic (PD) correlations were explored in 2 human abuse potential studies of orally and intranasally administered hydrocodone extended-release (ER) 45 mg in healthy, nondependent opioid users. In a crossover study design,subjects received intact hydrocodone ER,finely milled hydrocodone ER,and hydrocodone powder in solution in the oral study and finely milled hydrocodone ER, hydrocodone powder, and finely milled Zohydro R ER in the intranasal study. 
Rapid absorption and rapid onset of action of opioids have been associated with greater abuse potential 1 ; however, few studies have evaluated the relationship between pharmacokinetic (PK) and pharmacodynamic (PD; eg, drug liking) parameters in subjects receiving opioids. In a study evaluating the effects of exposure to fixed-dose combinations of oxycodone and acetaminophen in nondependent, recreational opioid users, a lower oxycodone concentration was correlated with less positive subjective drug effects when examined at the aggregate level (ie, using mean PK vs mean PD data). 2 The rate of rise in plasma drug concentration is another PK parameter that has been related to attractiveness for abuse, with higher peak concentration over a shorter time related to greater abuse potential. 3, 4 Support for this relationship has been demonstrated in studies of opioids, sedatives, and methylphenidate. [4] [5] [6] [7] [8] However, at the individual subject level, PK/PD correlations are often much weaker, suggesting that PK/PD relationships are highly variable and may depend on factors such as formulation or route of administration. 9, 10 An extended-release (ER) tablet formulation of hydrocodone (Vantrela R ER; Teva Pharmaceuticals, Inc., Frazer, Pennsylvania) was developed using the CIMA R Abuse-Deterrence Technology platform to provide resistance against the rapid release of hydrocodone when tablets are manipulated or taken with alcohol. 11 The results of 2 PK and PD human abuse potential studies in nondependent, recreational opioid users 1 Altreos Research Partners, Inc., Toronto, Canada 2 Teva Pharmaceuticals, Inc., Malvern, PA, USA demonstrated significantly lower abuse potential with hydrocodone ER tablets formulated with the AbuseDeterrence Technology platform vs hydrocodone controls when these were manipulated and administered orally or intranasally, 12, 13 which are the most common routes of hydrocodone abuse. [12] [13] [14] [15] PK findings from these studies demonstrated that barriers to rapid release of hydrocodone are retained when the medication is manipulated for oral or intranasal administration, limiting the rate and extent of rise of drug concentration after both oral ingestion and nasal insufflation of the manipulated product. 12, 13 An exploratory post hoc analysis of 2 human abuse potential studies was conducted to explore whether PK/PD correlations between the aggregate PK and PD data are also observed on an individual subject level. In data from the oral and intranasal human abuse potential studies of hydrocodone ER, we examined individual subject correlations between commonly derived PK and PD parameters in healthy subjects with a history of recreational opioid use.
Methods Participants
Eligible subjects were in good health, were aged 18 to 50 years in the oral study and 18 to 55 years in the intranasal study, were not physically dependent on opioids (as demonstrated by naloxone challenge), and had a history of recreational opioid use. In the intranasal study, subjects were also required to have reported experience with intranasal opioid use on ࣙ3 occasions in the year before screening.
Study Design
Detailed methodology for the oral and intranasal human abuse potential studies has been published previously. 12, 13 Briefly, both studies were single-dose, randomized, double-blind, placebo-and activecontrolled, crossover studies with a qualification phase to ensure that subjects could discriminate the effects of the positive control (45-mg dose of hydrocodone immediate release [IR]) vs those of placebo. Both were Category 3 studies; Category 2 data were also collected in the intranasal study. The studies were conducted in accordance with the International Conference on Harmonisation Good Clinical Practice Consolidated Guideline and applicable national and local laws and regulations. The study protocols were approved by an institutional review board before initiation (New England Institutional Review Board, Newton, Massachusetts). All subjects provided written informed consent before participating. Both studies were conducted at the same center (Lifetree Clinical Research, Salt Lake City, Utah).
In the oral study, subjects received 45-mg doses of intact oral hydrocodone ER, finely crushed oral hydrocodone ER, hydrocodone active pharmaceutical ingredient powder in solution, and placebo, separated by a ࣙ14-day washout. In the intranasal study, subjects received 45-mg doses of finely milled intranasal hydrocodone ER, intranasal hydrocodone active pharmaceutical ingredient powder, intact oral hydrocodone ER, finely milled intranasal Zohydro R ER (hydrocodone ER capsule commercially available from Zogenix, Inc., Emeryville, California, at the time of the study [before reformulation with BeadTek R Technology] 16 ), and placebo, separated by a ࣙ7-day washout. Data collected during placebo treatment in either study were not included in this post hoc analysis. For the intranasal study, the intact oral hydrocodone ER group was also excluded. Nonpharmacokinetic factors may influence intranasal subjective effects, and therefore only data from intranasally administered treatments were included in this post hoc analysis.
Results from an analysis for the intranasal study that included the intact oral hydrocodone ER group are included herein as supplemental data.
Bioanalytical Methods
Plasma levels of hydrocodone and its metabolite, hydromorphone, were quantitated using a validated high-performance liquid chromatography method with tandem mass spectrometric detection as previously described. 17 Briefly, a 100-μL matrix aliquot was fortified with 25 μL of 25 ng/mL internal standard (hydrocodone-d 3 and hydromorphone-d 3 ) working solution. Analytes were isolated through supported liquid extraction using Biotage Isolute SLE+ and eluted with 1.6 mL of dichloromethane. The eluate was evaporated, the remaining residue was reconstituted, and the final extract analyzed via a guard column (BetaSil Silica, 2.1 mm × 50 mm, 5 μm, Thermo Fisher, Waltham, Massachusetts), in conjunction with an analytical column (BetaSil Silica, 3.0 mm × 250 mm, 5 μm, Thermo Fisher), and eluted using a gradient of acetonitrile and water (92:8 → 70:30, v/v) containing 0.025% of trifluoroacetic acid. The analytes and internal standards were detected using positive ion electrospray. Transitions monitored were 300. Intraday and interday precision, expressed as coefficient of variation, was ࣘ15% (except at the lower limit of quantification, where ࣘ20% was acceptable). Interday and interday variability was within 15% of nominal at all concentrations (except the lower limit of quantification, where deviation was ࣘ20%). A linear, 1/concentration squared weighted, least-squares regression algorithm was used to quantitate unknown samples.
Pharmacodynamic and Pharmacokinetic Analyses
PD measures included in the current analysis were maximum effect (E max ) for (1) "At the moment" Drug Liking visual analog scale (VAS) assessed at time points up to 72 hours postdose in the oral study and up to 48 hours postdose in the intranasal study and (2) Overall Drug Liking VAS and Take Drug Again VAS at 24 hours postdose in the oral study and 12 and 24 hours postdose in the intranasal study. PD abuse quotient (PD AQ), defined as "at the moment" Drug Liking VAS E max /time to E max , was also calculated.
Plasma hydrocodone concentrations were measured before study drug administration and at the same postdose time points as "at the moment" Drug Liking VAS assessments. PK parameters calculated for the current analysis of hydrocodone included maximum observed plasma drug concentration (C max ), time to C max (T max ), area under the plasma hydrocodone concentration-time curve (AUC) to 4 hours postdose (AUC 0-4h ) in the oral study (approximate T max of finely crushed oral hydrocodone ER 13 ), and AUC from time 0 to T max of finely milled intranasal hydrocodone ER (AUC 0-Tmax,IN HCO ER ) in the intranasal study (2.6 hours postdose 12 ). PK AQ also was calculated as C max /T max . Although AQ is not a validated measure of slope (ie, rate of rise), it provides a summary measure of 2 potentially important individual PK factors and has been included in a number of other abuse potential studies.
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Statistical Analysis
For this exploratory, post hoc analysis, associations between individual PK and PD data were analyzed by study using correlation coefficients within each treatment separately and for all treatments together. Initially, associations were analyzed using Pearson correlations (r). However, because nonlinear relationships between PK and PD variables were observed, the data were also analyzed using Spearman rank-order correlations (ρ) to measure the strength and direction of the monotonic relationship. The r and ρ coefficients were squared to indicate the fraction of variance in the PD measures explained by PK variables, and r 2 and ρ 2 values are reported. Scatterplots were generated based on rank-order and raw data to illustrate the distribution of the individual subject data.
Results
Oral Study
Forty-five subjects for whom PK and PD data were available were included in the analyses. No association was seen between PD AQ ("at the moment" Drug Liking VAS E max /time to E max ) and PK AQ. Figure 1 presents scatterplots showing the distribution of individual subject data (A) and rank-order data (B) for selected PK and PD parameters for all treatments. Relationships are most apparent between "at the moment" Drug Liking VAS E max and PK parameters.
Intranasal Study
Thirty-four subjects were evaluable for the PK/PD analysis. No clear correlations were observed in the intranasal study, either for each treatment separately (Table S1 ) or in the analysis of data from all treatments (no ρ 2 or r 2 values >0.07 were observed; Table 1 ). When the intact oral hydrocodone ER group was included in the analysis of all treatments, ρ 2 and r 2 values for all comparisons (except ρ 2 for PD AQ vs PK AQ) were larger than those observed when the intact oral hydrocodone ER group was excluded (ρ 2 = 0.0001 to 0.3122 vs 0.0060 to 0.0620; r 2 = 0.0085 to 0.3123 vs 0.0000 to 0.0676, respectively; Table S2 ). However, they were not as large as ρ 2 and r 2 values in the oral study. Figure 2 presents scatterplots showing the distribution of subject data (A) and rank-order data (B) from the intranasal study for selected PK and PD comparisons. Data for all treatments excluding the intact oral hydrocodone ER group are shown. No clear relationships are apparent in the data from the intranasal study.
Discussion
This exploratory, post hoc analysis of data from 2 human abuse potential studies in healthy subjects with a history of recreational opioid use evaluated potential correlations between hydrocodone PK and subjective PD parameters. In the oral study, the results suggested that PK measures, specifically higher and earlier peak plasma concentrations (C max and T max ) and higher early systemic exposure (AUC 0-4h ), are associated with increased "at the moment" Drug Liking, Overall Drug Liking, and Take Drug Again VAS scores in an analysis of all treatments. Based on ρ 2 values, variation in PK parameters explained approximately 45% to 50% of the variation in "at the moment" Drug Liking VAS E max in that study. In the intranasal study, analysis of data from all treatments (excluding the intact oral hydrocodone ER group) found no clear relationship between PK and PD measures. The average rate of rise of plasma hydrocodone concentrations (PK AQ) was not directly related to the average rate of rise of "at the moment" Drug Liking (PD AQ) in either study. Correlations were stronger in the oral study, which is consistent with the concept that intranasal abuse potential and liking may be more influenced by non-PK factors, such as local effects of the formulation, than oral abuse potential. Correlations between PK and PD parameters within individual treatments were generally much weaker, likely owing to insufficient range in the PD scores or plasma concentrations and too few data points to show a correlation.
The individual subject PK/PD correlations observed in the post hoc analysis for the oral study appear to be stronger than those reported in previous studies. 9, 10 These findings may be related to the very slow kinetics and lack of abuse-related effects with intact oral hydrocodone ER, which may have provided a broader range of PD responses compared with findings of other studies of abuse-deterrent opioid formulations, 9, 10 and to a lack of abuse-related effects (ie, similar to placebo) with intact oral hydrocodone ER. 12, 13 Indeed, ρ 2 and r 2 values were generally greater in the intranasal study when the intact oral group was included in the analysis.
There are several limitations to this analysis. Zohydro R ER, which was used as a comparator in the intranasal study, does not have abuse-deterrence labeling but was included because it was the only commercially available ER formulation of hydrocodone available at the time of the study. This was an exploratory post hoc analysis of registration-focused premarket studies, and the data were not derived from Intranasal study: pharmacokinetic vs pharmacodynamic measures, individual subject raw data (A) and rank-ordered data (B) for all treatments (excluding data from the intact oral hydrocodone ER group). AQ, abuse quotient; AUC 0-Tmax,IN HCO ER , area under the plasma drug concentration-time curve from time 0 to T max of intranasal hydrocodone ER; C max , maximum observed plasma drug concentration; E max , maximum effect; PD, pharmacodynamic; PK, pharmacokinetic; T max , time to C max ; VAS, visual analog scale. studies prospectively designed to evaluate PK/PD relationships. As such, this analysis was limited by the design of the included studies, such as the use of only 1 dose level of the study drugs. Additional dose levels may have helped further define the PK/PD relationship by providing more dynamic range in the plasma concentrations. In addition, the analysis was not hypothesis driven but rather an exploratory examination of a number of potential PK and PD variables using data that were previously examined in the studies' protocol-specified analyses, prior to planning and performing the current analysis. Given the exploratory nature of the analysis, no adjustments for multiplicity were undertaken, and low P values, even those in which relationships were weak, may be due to the relatively large number of comparisons. In addition, the relatively large sample size of the studies (n = 45 and n = 34) may have contributed to the statistical significance of some of the relationships. For this reason, the data were evaluated for potential clinical relevance using ρ 2 or r 2 values and not P values. In this context, the weak relationships associated with low P values in the intranasal study were most likely of limited clinical relevance. Although ρ 2 or r 2 values associated with low P values in the oral study were higher, the clinical importance of these correlations is not known. Further research is needed to better understand PK-PD relationships in abuse potential studies, as other types of analyses (eg, factor analysis, hysteresis loop plots) and parameters (eg, slope of PD effects) may potentially provide additional information on the nature of these relationships. Finally, while this exploratory study showed moderate correlations between some PK and PD variables examined in the oral study, indicating that PK factors may play a role in the abuse potential of opioids in some situations, this may not necessarily be generalizable to other products or studies. This analysis does not suggest that PK data could be used to predict individual PD responses, which may be influenced by very many factors other than PK, nor that PK data should in any way replace the more robust PD evaluations of abuse potential.
In conclusion, although these post hoc analyses of data from human abuse potential studies of hydrocodone ER formulated with Abuse-Deterrence Technology are exploratory and should be interpreted with caution, PK and subjective PD effects showed some correlation in the oral study, and suggest that in some situations, lower and later plasma concentrations may be associated with lower drug liking on an individual subject level. However, the clinical relevance of these correlations is not known. In addition, no clear PK-PD relationships were apparent in the intranasal study. A greater understanding of the relationship between PK and PD activity of opioids may inform the development of drugs formulated to reduce the potential for abuse.
